- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07673081
Real-World Effectiveness of RSV Vaccines Among Adults Using Target Trial Emulation in Epic Cosmos
REAL-WORLD EFFECTIVENESS OF RSV VACCINES AMONG ADULTS USING TARGET TRIAL EMULATION IN EPIC COSMOS
Among non-pregnant adults observed in Epic Cosmos since August 2023 who are eligible for RSV vaccination, what is the effectiveness of ABRYSVO® (RSVpreF), compared with unvaccinated individuals, in preventing RSV-related and all-cause acute respiratory illness (ARI), lower respiratory tract disease (LRTD), and other outcomes of interest, within a target trial emulation (TTE) framework
Studieoversikt
Status
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiesteder
-
-
New York
-
New York, New York, Forente stater, 10001
- Pfizer
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
The study population will include non-pregnant adults aged ≥18 years and ≥ 60 years in the United States with care observed in Epic Cosmos, contributing healthcare systems on or after August 2023. Individuals will be required to have sufficient healthcare engagement to ensure adequate data capture and observability within the database. Within this population, vaccinated individuals will be identified by documented administration of an RSV vaccine in structured EHR data.
Beskrivelse
Inclusion:
Vaccinated Cohort
Patients must meet all the following inclusion criteria to be eligible for inclusion in the study:
- Adults meet the age criteria at the index date.
- Non-pregnant at the index date.
- Have at least one clinical encounter recorded in Epic Cosmos database during the 12 months prior to the index date.
- Have a documented administration of ABRYSVO® (or AREXVY®,mRESVIA® in the later phase) in Epic Cosmos on or after August 2023.
The index date for vaccinated individuals will be defined as the date of RSV vaccination.
Unvaccinated Cohort
Patients must meet all the following inclusion criteria to be eligible for inclusion in the study (in unvaccinated cohort):
- Adults meet the age criteria at the index date.
- Non-pregnant at the index date.
- Have at least one clinical encounter recorded in Epic Cosmos database during the 12 months prior to the index date.
- Have no documented receipt of any RSV vaccine in Epic Cosmos on or prior to the trial start date.
The index date for unvaccinated individuals will be defined as the start date of each sequential trial ('e.g.', 1st date of each month) in which they met eligibility criteria
Exclusion:
Exclusion Criteria Vaccinated Cohort
Patients meeting any of the following criteria will not be included in the study:
- Individual with receipt of any RSV vaccine in Epic Cosmos prior to the trial start date, as defined above (applicable to all analyses except for the analysis of recipients of multiple doses).
- Non-US residents. Unvaccinated Cohort
Patients meeting any of the following criteria will not be included in the study (in unvaccinated cohort):
- Individual with receipt of any RSV vaccine in Epic Cosmos on or prior to the trial start date, as defined above.
- Non-US residents. Patients must meet all the inclusion criteria and none of the exclusion criteria to meet eligibility requirements
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: RETROSPECTIVE
Kohorter og intervensjoner
Gruppe / Kohort |
|---|
|
Vaccinated group
Individuals with documented receipt of an RSV vaccine in EHR data. Vaccines included: ABRYSVO® (Pfizer),AREXVY® (GSK), mRESVIA® (Moderna) |
|
Unvaccinated comparator group:
Individuals not yet vaccinated at cohort entry, but otherwise eligible |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Incidence of RSV-related Acute Respiratory Infection (ARI) hospitalization
Tidsramme: up to 3 years
|
up to 3 years
|
|
Incidence of RSV-related Lower Respiratory Tract Disease (LRTD) hospitalization
Tidsramme: up to 3 years
|
up to 3 years
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of RSV-related outcomes
Tidsramme: up to 3 years
|
ARI/LRTD non-inpatient encounter, ARI/LRTD severe outcome, ARI/LRTD critical outcome, CV events with different care settings, thromboembolic event with different care settings, asthma exacerbation with different care settings, COPD exacerbation with different care settings, Immunocompromised status and pneumonia with different care settings. |
up to 3 years
|
|
Incidence of All-cause outcomes
Tidsramme: up to 3 years
|
all-cause ARI/LRTD encounter with different care settings, severe outcome, critical outcome, CV events with different care settings, thromboembolic event with different care settings, asthma exacerbation with different care settings, COPD exacerbation with different care settings, pneumonia with different care settings, Immunocompromised status and dementia (new onset). |
up to 3 years
|
Samarbeidspartnere og etterforskere
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- C3671094
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .